⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

WST · West Pharmaceutical Services, Inc.

$331.25 latest stored close
Detected setup Wyckoff SOS

Watch · Quality 22/100

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about WST

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / WST

$WST

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $23B.

Neutral · 50 Health Technology Medical Specialties stock Stage 2 · Advancing Base 1 ⚡ Scan vol 2.0× Data 1h 0m ago
$331.25 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 4 watch · 2 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Normal technical setup

Thursday, July 23, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

WST+0.93%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. WST was +0.42 points vs XLV. +0.91 points vs SPY. Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $331.25 Jul 27 close
52W High $386.00 -14.2%
52W Low $223.83
Wks Since High 0w
Base Depth -15.7%
Base B1
SMA 50 $335.31
SMA 200 $283.40
Avg Vol 794,657
RS Rank 55
RS vs High -8.7%
RS Slope -6.4% ▼
Grp Rank #48/64
ADR% 2.9%
ATR(14) $11.45 (3.5%)
Rel Vol (today) 2.02×
Vol Pace N/A
U/D Vol 0.92
A/D Days 15A / 10D
A/D Rating A+
VDU Bars 0/10 d
Earnings past
$223.83
$386.00 66%

WST Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for WST.

Create Free Account
Setup Quality D 2/7 signals
Jul 23: 55 (Power Play)Jul 24: 55 (Wyckoff SOS)Jul 28: 47 (Wyckoff SOS)Jul 28: 55 (Wyckoff SOS)55 Score trend
✓ Stage 2 · Advancing ✗ Power Trend ✗ RS New High ✓ Trend 6/8 ✗ No Pattern ✗ CANSLIM 59.7 (C) ✗ Gatekeeper Base #1 (A)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$WST · $331.25 · as of 2026-07-27 · multi-factor read
50
/ 100
Neutral

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating
Weekly ▬ Sideways / consolidating
Monthly ▬ Sideways / consolidating

Moving Averages

50-day$335.31 ↓
100-day$301.89 ↑
200-day$283.40 ↑
Bullish (50 > 200)

RSI (14)

Reading39.1 · Bearish

Bearish momentum — sellers in control.

MACD (12/26/9)

StateWeakening
Histogram-4.448

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width-14% · 10.6%

Piercing the lower band — capitulation or strong selling.

Volume · Buyer vs Seller

Up/Down vol0.92 · Neutral
Rel volume2.02×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is expanding versus its baseline.

Support & Resistance

R · $336.82swing level
R · $367.66swing level
R · $386.0052-week high
Price · $331.25now
S · $321.94swing level
S · $295.90swing level
S · $240.16swing level

Fibonacci · Uptrend swing

23.6%$348.59
38.2%$325.45
50.0%$306.75
61.8%$288.04
78.6%$261.41

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for WST — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Above 200-day MA50/200 bullish
Want this read in a legend's voice? 💬 Ask a Legend about WST
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 4 of 6 legends are Watching — building, not yet a confirmed buy.
Avoid
Minervini C

Trend-template read: fails Price > 50-day MA.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $331.25, MA150 $286.64, MA200 $283.40
1.2 150-day MA > 200-day MAMA150 $286.64 vs MA200 $283.40
Failing evidence
1.5 Price > 50-day MAPrice $331.25 vs MA50 $335.31
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 55
8/13 checks
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
A: Annual earnings & revenue qualityRev +6.2% | ROE 17.9%
N: Near 52-week high or RS line new high14.2% below high | RS line new high: False
Failing evidence
C: Quarterly EPS acceleration ≥ 25%+4.4% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 55
4/8 checks
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $331.25 vs MA200 $283.40
Failing evidence
Relative strength ≥ 60RS 55
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$331.25
Volume vs average2.02x
Failing evidence
Relative strengthRS 55
5/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$331.25
Volume vs average2.02x
Failing evidence
Relative strengthRS 55
5/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$331.25
Volume vs average2.02x
Failing evidence
Relative strengthRS 55
5/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▼ Falling
111RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +3 A+
A: 18 D: 15 Net: +365 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B 4/7 SEPA
Separate score from the 8-point Trend Template (6/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ +4%
Revenue growth ≥20% YoY +6%
Gross margin ≥30% 36%
ROE ≥17% 18%
RS rating ≥80 (leadership) 55
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -14.2%

Method Playbook

📋 Trade it like Wyckoff EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
Wyckoff B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the Spring/test, Sign of Strength, creek, or Last Point of Support boundary identified by the active structure.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a completed test or Sign of Strength/Last Point of Support confirmation with improving demand versus supply.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the Spring/test low or structural support whose failure would invalidate the accumulation read.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Raise protection beneath successive Last Points of Support or meaningful higher lows during markup; never loosen it.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a failed Sign of Strength, support loss, or clear supply-dominant reversal such as an upthrust failure.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Wyckoff SOS ⚠ Volatility widening into breakout ⚠ Extended past buy zone ⚠ 3rd-stage base ⚠ Rising wedge (broke lower) ⚠ Not actionable yet
47.0 score
RS Score 55
Trend 6/8
CANSLIM 59.7* (C)
range low: 236.337 range high: 309.995 range pct: 0.312 sos thrust: 0.147 sos vol ratio: 1.935 sos bars ago: 2 near lps: ✓ validation reason: valid generic setup multi tf evaluated: ✓ multi tf reason: weekly: MA stabilizing or rising — accumulation context supported
Why This Setup?
Wyckoff SOS

SOS: breakout above range_high=309.99, thrust=14.7%, vol=1.9x avg, lps=near, 2 bars ago | Moderate trend (6/8) | High-confidence pattern (85%) | Volume surging | Stage 2 | Recent gap-up (2d ago) | Readiness 62/100 (early) | CANSLIM 59.7 (C) | ⚠ Volatility widening into breakout; Extended past buy zone; 3rd-stage base; Rising wedge (broke lower); Not actionable yet

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

2/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

6/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $331.25 vs SMA150 $286.64 / SMA200 $283.40
SMA 150 above SMA 200 SMA150 $286.64 vs SMA200 $283.40
SMA 200 trending up Slope +9.49 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $335.31
Price above SMA 50 $331.25 vs SMA50 $335.31
30%+ above 52W low +48.0% from $223.83
Within 25% of 52W high -14.2% from $386.00
RS score above 70 RS 55

Fundamentals

52W Range
66%
Mkt Cap SEC
23.3B
EPS QoQ
+4%
Rev YoY
+6%
ROE
18%
Gross Margin
36%
D/E
0.07
EPS TTM
$6.79
P/E TTM
48.8x
Float
70M
Insider
No Buy

Company

Legend AI snapshot
West Pharmaceutical Services, Inc.
WST · NYSE · Health Technology · Medical Specialties
$331.25latest close $23.3Bmarket cap 55RS rank 47setup score
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
C 59.7* CANSLIM * disqualified on C, M
C · Curr. EPS
62
A · Annual EPS
71
N · New Highs
40
S · Supply/Demand
100
L · Leader RS
55
I · Inst. Spons.
50
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
7/8
W. RS
80
W. Support
$223.83
W. Resist
$386.00
Weekly Structure

Scan History

4× streak
Jul 23: 55 (Power Play)Jul 24: 55 (Wyckoff SOS)Jul 28: 47 (Wyckoff SOS)Jul 28: 55 (Wyckoff SOS)55
Jul 28
Wyckoff SOS ✓ Gate
55
Jul 28
Wyckoff SOS
47
Jul 24
Wyckoff SOS ✓ Gate
55 +0.9%
Jul 23
Power Play ✓ Gate
55 -6.8%

Get the full picture on WST

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial